Literature DB >> 21525338

Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions.

Hongjie Wang1, ZongYi Li, Roma Yumul, Stephanie Lara, Akseli Hemminki, Pascal Fender, André Lieber.   

Abstract

Recently, we identified desmoglein 2 (DSG2) as the main receptor for a group of species B adenoviruses (Ads), including Ad3, a serotype that is widely distributed in the human population (H. Wang et al., Nat. Med. 17:96-104, 2011). In this study, we have attempted to delineate structural details of the Ad3 interaction with DSG2. For CAR- and CD46-interacting Ad serotypes, attachment to cells can be completely blocked by an excess of recombinant fiber knob protein, while soluble Ad3 fiber knob only inefficiently blocks Ad3 infection. We found that the DSG2-interacting domain(s) within Ad3 is formed by several fiber knob domains that have to be in the spatial constellation that is present in viral particles. Based on this finding, we generated a small recombinant, self-dimerizing protein containing the Ad3 fiber knob (Ad3-K/S/Kn). Ad3-K/S/Kn bound to DSG2 with high affinity and blocked Ad3 infection. We demonstrated by confocal immunofluorescence and transmission electron microscopy analyses that Ad3-K/S/Kn, through its binding to DSG2, triggered the transient opening of intercellular junctions in epithelial cells. The pretreatment of epithelial cells with Ad3-K/S/Kn resulted in increased access to receptors that are localized in or masked by epithelial junctions, e.g., CAR or Her2/neu. Ad3-K/S/Kn treatment released CAR from tight junctions and thus increased the transduction of epithelial cells by a serotype Ad5-based vector. Furthermore, the pretreatment of Her2/neu-positive breast cancer cells with Ad3-K/S/Kn increased the killing of cancer cells by the Her2/neu-targeting monoclonal antibody trastuzumab (Herceptin). This study widens our understanding of how Ads achieve high avidity to their receptors and the infection of epithelial tissue. The small recombinant protein Ad3-K/S/Kn has practical implications for the therapy of epithelial cancer and gene/drug delivery to normal epithelial tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525338      PMCID: PMC3112237          DOI: 10.1128/JVI.00514-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells.

Authors:  Isabel J Latorre; Michael H Roh; Kristopher K Frese; Robert S Weiss; Ben Margolis; Ronald T Javier
Journal:  J Cell Sci       Date:  2005-09-01       Impact factor: 5.285

2.  Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.

Authors:  S Ni; A Gaggar; N Di Paolo; Z Y Li; Y Liu; R Strauss; P Sova; J Morihara; Q Feng; N Kiviat; P Touré; P S Sow; A Lieber
Journal:  Cancer Gene Ther       Date:  2006-07-28       Impact factor: 5.987

3.  Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Authors:  Eva A Turley; Mandana Veiseh; Derek C Radisky; Mina J Bissell
Journal:  Nat Clin Pract Oncol       Date:  2008-03-18

4.  Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1).

Authors:  Ziping Yang; Micha Horn; Joanne Wang; Danny D Shen; Rodney J Y Ho
Journal:  AAPS PharmSci       Date:  2004-03-09

5.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.

Authors:  Robert Strauss; Pavel Sova; Ying Liu; Zong Yi Li; Sebastian Tuve; David Pritchard; Paul Brinkkoetter; Thomas Möller; Oliver Wildner; Sari Pesonen; Akseli Hemminki; Nicole Urban; Charles Drescher; André Lieber
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

6.  Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment.

Authors:  Mary L Disis
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

Review 7.  Adenovirus receptors: implications for tropism, treatment and targeting.

Authors:  Niklas Arnberg
Journal:  Rev Med Virol       Date:  2009-05       Impact factor: 6.989

8.  Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier.

Authors:  N Sonoda; M Furuse; H Sasaki; S Yonemura; J Katahira; Y Horiguchi; S Tsukita
Journal:  J Cell Biol       Date:  1999-10-04       Impact factor: 10.539

Review 9.  Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo.

Authors:  Robert Strauss; André Lieber
Journal:  Curr Opin Mol Ther       Date:  2009-10

10.  Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35.

Authors:  Sebastian Tuve; Hongjie Wang; Jeffrey D Jacobs; Roma C Yumul; David F Smith; André Lieber
Journal:  PLoS Pathog       Date:  2008-10-31       Impact factor: 6.823

View more
  42 in total

1.  Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.

Authors:  Ines Beyer; Hua Cao; Jonas Persson; Hui Song; Maximilian Richter; Qinghua Feng; Roma Yumul; Ruan van Rensburg; Zongyi Li; Ronald Berenson; Darrick Carter; Steve Roffler; Charles Drescher; André Lieber
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

2.  Junction opener protein increases nanoparticle accumulation in solid tumors.

Authors:  Christine E Wang; Roma C Yumul; Jonathan Lin; Yilong Cheng; André Lieber; Suzie H Pun
Journal:  J Control Release       Date:  2018-01-03       Impact factor: 9.776

3.  1. Alternative splicing of viral receptors: A review of the diverse morphologies and physiologies of adenoviral receptors.

Authors:  Katherine J D A Excoffon; Jonathan R Bowers; Priyanka Sharma
Journal:  Recent Res Dev Virol       Date:  2014

4.  Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1.

Authors:  Hongjie Wang; Corinne Ducournau; Kamola Saydaminova; Maximilian Richter; Roma Yumul; Martin Ho; Darrick Carter; Chloé Zubieta; Pascal Fender; André Lieber
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

Review 5.  The role of epithelial tight junctions involved in pathogen infections.

Authors:  Ru-Yi Lu; Wan-Xi Yang; Yan-Jun Hu
Journal:  Mol Biol Rep       Date:  2014-06-26       Impact factor: 2.316

6.  Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection.

Authors:  Hung V Trinh; Guillaume Lesage; Venus Chennamparampil; Benedikt Vollenweider; Christoph J Burckhardt; Stefan Schauer; Menzo Havenga; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

7.  Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.

Authors:  Charles Vragniau; Jens-Martin Hübner; Peter Beidler; Sucheol Gil; Kamola Saydaminova; Zhuo-Zhuang Lu; Roma Yumul; Hongjie Wang; Maximilian Richter; Pavel Sova; Charles Drescher; Pascal Fender; André Lieber
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

8.  Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells.

Authors:  Mallory A Turner; Sumit Middha; Sean E Hofherr; Michael A Barry
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

9.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

10.  Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models.

Authors:  Roma Yumul; Maximilian Richter; Zhuo-Zhuang Lu; Kamola Saydaminova; Hongjie Wang; Chung-Huei Katherine Wang; Darrick Carter; André Lieber
Journal:  Hum Gene Ther       Date:  2016-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.